Drug Profile

BOXR 1030

Alternative Names: BOXR-1030

Latest Information Update: 18 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Unum Therapeutics
Developer SOTIO
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Liver cancer; Lung cancer; Merkel cell carcinoma; Myxoid liposarcoma

Most Recent Events

10 Nov 2022 Pharmacodynamics data from preclinical study in Cancer released by SOTIO Biotech
10 Nov 2022 SOTIO Biotech plans a DUET-01 trial for BOXR 1030 in coming months
01 May 2022 Phase-I/II clinical trials in Liver cancer (Late-stage disease, In adults, In the elderly) in USA (IV) (NCT05120271)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com